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Abstract
Background Enzyme-replacement therapy (ERT) in Pompe
disease—an inherited metabolic disorder caused by acid α-
glucosidase deficiency and characterized in infants by gener-
alized muscle weakness and cardiomyopathy—can be com-
plicated by immune responses. Infants that do not produce any
endogenous acid α-glucosidase, so-called CRIM-negative pa-
tients, reportedly develop a strong response. We report the
clinical outcome of our Dutch infants in relation to their CRIM
status and immune response.
Methods Eleven patients were genotyped and their CRIM
status was determined. Antibody formation and clinical out-
come were assessed for a minimum of 4 years.
Results ERTwas commenced between 0.1 and 8.3 months of
age, and patients were treated from 0.3 to 13.7 years. All
patients developed antibodies. Those with a high antibody
titer (above 1:31,250) had a poor response. The antibody titers
varied substantially between patients and did not strictly cor-
relate with the patients’ CRIM status. Patients who started
ERT beyond 2 months of age tended to develop higher titers
than those who started earlier. All three CRIM-negative pa-
tients in our study succumbed by the age of 4 years seemingly
unrelated to the height of their antibody titer.
Conclusion Antibody formation is a common response to
ERT in classic infantile Pompe disease and counteracts the
effect of treatment. The counteracting effect seems determined
by the antibody:enzyme molecular stoichiometry. The im-
mune response may be minimized by early start of ERT and
by immune modulation, as proposed by colleagues. The
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Introduction
Immune responses are common in lysosomal storage disor-
ders (LSDs) in which enzyme-replacement therapy (ERT) is
applied (Brooks et al 2003; Wang et al 2008). The aim of ERT
is to correct the enzyme deficiencies in LSDs by intravenous
infusion of recombinant human enzymes. ERT is now available
for Gaucher disease, Fabry disease, the mucopolysaccharidoses
(MPS I, II and VI), and for Pompe disease. Immune responses
have been seen in all these diseases (Brooks et al 2003; Wang
et al 2008).
Pompe disease (glycogen storage disease type II, acid malt-
ase deficiency, OMIM # 232300) is a lysosomal storage disor-
der caused by mutations in the acid α-glucosidase gene (GAA,
EC 3.2.1.20) (Hirschhorn and Reuser 2001; van der Ploeg and
Reuser 2008). The disease is autosomal recessive and has a
broad clinical spectrum (Güngör and Reuser 2013). At the
severe end of the spectrum, patients with classic infantile
Pompe disease present with muscle weakness, hypertrophic
cardiomyopathy and respiratory insufficiency in the first few
months of life. If untreated, they usually succumb to cardio-
respiratory insufficiency before the end of their first year (van
den Hout et al 2003; Kishnani et al 2006a). Their rapid demise
is caused by a virtually total deficiency of acid α-glucosidase
activity. Treatment with alglucosidase alfa reverses the cardio-
myopathy, improves motor function, and extends the survival
of patients with classic infantile Pompe disease (Van den Hout
et al 2000, van den Hout et al 2004; Klinge et al 2005a; Klinge
et al 2005b; Kishnani et al 2006b, 2007; Nicolino et al 2009;
Kishnani et al 2009; Chakrapani et al 2010).
Over 95 % of affected infants receiving ERT develop
antibodies to alglucosidase alfa (Kishnani et al 2010). In
classic infantile Pompe disease, a distinction is often made
between CRIM-negative patients (cross reactive immunolog-
ical material) who lack any form of endogenous acid α-
glucosidase and CRIM-positive patients who synthesize some
catalytically inactive acid α-glucosidase. High and sustained
antibody titers were reported to occur mainly in CRIM-
negative patients and to be associated with a poor clinical
outcome (Kishnani et al 2010; Banugaria et al 2011). Here
we report on the immune response to ERT in 11 patients with
classic infantile Pompe disease who were treated for up to
13 years. We examined 1.) the relationship between antibody
formation and the patients’ CRIM status and 2.) the impact of
antibody formation on the patients’ clinical outcome.
Materials and methods
Patients
We describe 11 patients with classic infantile Pompe disease
who received ERT in our hospital between 1999 and 2012.
Classic infantile Pompe disease was defined as symptoms of
muscle weakness within 6 months after birth; hypertrophic
cardiomyopathy (left ventricular mass index (LVMI)>+2SD
(>75 g/m2) (Poutanen and Jokinen 2007)); less than 1 % acid
α-glucosidase activity in fibroblasts; and severe mutations in
both GAA alleles. Activity assays and mutation analysis were
performed as described previously (Kroos et al 1997, 2007).
All patients participated in consecutive trials investigating the
safety and efficacy of ERT (20 mg/kg every other week to
40 mg/kg weekly). Initially, four patients received recombi-
nant human α-glucosidase from the milk of transgenic rabbits
(Van den Hout et al 2000). From 2004 onward, all patients
were treated with alglucosidase alfa. The Institutional Review
Board approved all studies and the parents of all patients gave
written informed consent.
CRIM status
Two methods were used to determine the patients’ CRIM
status. Cultured skin fibroblasts from the patients were used
in the first method. They were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10 % fetal calf
serum (FCS) and antibiotics, and were harvested with trypsin
1 week after reaching confluence. Frozen cell pellets were
lysed in 10 mM phosphate-buffered saline (PBS) pH 7.0
containing 1 % Triton-X100 and protease inhibitors. A
10 μL aliquot containing 100 μg protein was mixed with
10 μL sample buffer (NuPAGE, LDS sample buffer, Life
Technology, with 4 % SDS instead of 0.84 %) and applied
to SDS-PAGE (Bio-Rad Criterion XT 4–12 % MOPS gel
system). After blotting onto nitrocellulose the various molecular
forms of acid α-glucosidase were visualized with polyclonal
rabbit antibodies against recombinant-human acid α-glucosidase
and goat anti-rabbit IRDye 680LTas secondary antibody using an
Odyssey infrared imager (LI-COR Biosciences).
The second method for determining the CRIM status was
based on transient expression of GAA cDNA constructs con-
taining the patients’ pathogenic mutations in HEK293T cells
(onemutation per construct). The activity of acidα-glucosidase
in these cells and in the culture medium was measured with the
artificial substrate 4-methylumbelliferyl-α-D-glucopyranoside
(MUGlc, Sigma) at 72 h after transfection. The biosynthetic
forms of acidα-glucosidase were separated by SDS-PAGE and
visualized by immunoblotting (Hermans et al 1998).
Antibody detection
Blood samples for antibody titer measurements were drawn
before the start of ERT and every 3 months thereafter just
before the start of enzyme infusion. The sera were stored at
-20°C. An enzyme-linked immunosorbent assay (ELISA) was
used to determine the titers. To this end a 96-well plate (Nunc,
F96 Maxisorp, Denmark) was coated with 50 μL/well
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alglucosidase alfa in a concentration of 5 μg/mL, diluted in
PBS (pH 7.4), and incubated for 2 h at room temperature
under continuous shaking. Plates were blocked overnight at
4°C with a solution of bovine serum albumin (BSA; Sigma
A7030) in PBS (1 % weight/volume). The plates were rinsed
six times at room temperature with 200 μL washing buffer
(0.05 % Tween-20 in PBS). Plates were then incubated with
50 μL of five-fold serial dilutions of patients’ sera for 1 h
during shaking. Samples were diluted from 50 to 3,906,250
fold in dilution buffer (BSA/PBS containing 0.05 % Tween-
20). Sera from healthy individuals were used as negative
controls, and rabbit antiserum against alglucosidase alfa as a
positive control. After washing of the plates, 50 μL conjugate
was added to each well: polyclonal goat-anti-human-[IgG,
IgA and IgM]-HRP (Acris) in a 20,000-fold dilution for
human sera, and goat-anti-rabbit-IgG-HRP (Sigma) in a
10,000-fold dilution for rabbit serum. After 1 h incubation at
room temperature followed by thorough washing, 100 μL
Tetramethylbenzidine Microwell Peroxidase substrate
(Kirkegaard and Perry Laboratories, Maryland) was added,
and the plates were incubated for 10 min. The colorimetric
reaction was stopped by the addition of 100 μL 1M phosphoric
acid (H3PO4). Absorbance was measured at 450 nm with a
spectrophotometer (Thermo Electron Corporation, Vantaa,
Finland). The maximal dilution at which absorbance was at
least twice that of the negative control was taken as titer.
An antibody titer assay based on immunoprecipitation of
alglucosidase alfa was used as second semi-quantitative meth-
od (de Vries et al 2010).
Inhibition of alglucosidase alfa uptake
Fibroblasts from a patient homozygous for the 525delT mu-
tation fully deficient in acid α-glucosidase production were
seeded in 24-well tissue-culture plates and maintained at 37°C
in Ham’s F10 medium supplemented with 10 % FCS and
antibiotics. To measure the uptake of alglucosidase alfa, we
added Pipes to the medium in a final concentration of 3 mM to
make the medium slightly acidic (pH 6.8). The enzyme was
added in an amount equivalent to 200 nmol MUGlc/h per
200 μL medium. Finally, 20 μL of the patients’ sera were
added. The acid α-glucosidase activity in the medium was
measured directly after enzyme addition and prior to cell
harvest. Uptake of alglucosidase alfa was measured in cell
homogenates. MUGlc was used as substrate.
Clinical assessments
The clinical outcome was evaluated by analyzing survival,
ventilator use, gross motor function, and cardiac dimensions at
baseline and at regular intervals; the latter by 2D-guided M-
mode echocardiography. The LVMI was calculated as a mea-
sure for hypertrophic cardiomyopathy. Motor development
was assessed using the Alberta Infant Motor Scale (AIMS)
(Piper and Darrah 1994).
Safety assessments included the monitoring of infusion-
associated reactions (IARs). All adverse events that were
judged to be possibly, probably or definitely related to ERT
were considered IARs.
Statistical analysis
Due to limitations in patient numbers, the clinical data was
summarized using descriptive statistics. All patients were
followed-up for at least 4 years after the start of ERT, or until
death. Data were analyzed using SPSS for Windows version
20, SPSS Inc., Chicago, IL.
Results
Patients
This study describes 11 patients (five boys and six girls) with
classic infantile Pompe disease (Table 1). All had symptoms
before the age of 3.5 months; nine started ERT before the age
of 4 months. Two patients started ERT at the ages of 7 and
8 months when they were severely affected. All 11 patients
had cardiac hypertrophy, less than 1 % of average normal acid
α-glucosidase activity in cultured fibroblasts, and a severe
mutation in both GAA alleles (Table 1). They were treated
with ERT for 0.3 to 13.7 years (median duration 5.6 years).
CRIM status
‘CRIM status’ in this study is defined as the ability to detect
any acid α-glucosidase with immunological methods in either
the patients’ cultured fibroblasts or in HEK293 cells in which
mutated GAA constructs with the patients’ mutations were
expressed. A CRIM-positive status indicates that molecular
forms of acid α-glucosidase could be detected. A CRIM-
negative status indicates that these were undetectable.
Figure 1 presents an example of the first type of analysis in
fibroblasts. Cell homogenates were analyzed by SDS-PAGE
followed by immunoblotting. Compared to normal synthesis
of acid α-glucosidase in fibroblasts of a healthy individual
(Wt), represented by the presence of a 110 kD precursor and
molecular species of 95, 76 and 70 kD, fully maturated
enzyme of 76 kD was not detected in cells from any of the
patients. However, the 110 kD precursor was detected in eight
cases. In four of these cases (pts 1, 3, 10, and 11), the apparent
molecular mass of the precursor was near normal. In the other
four cases (pts 2, 5, 6, and 9), the mass was abnormally low
due to either homozygosity or heterozygosity for the rather
common exon 18 deletion (c.2481+102_2646+31del). Pro-
teolytic conversion of the 110 kD precursor to the 95 kD
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intermediate could be demonstrated only in cells of patient 9.
Three patients did not have any trace of acid α-glucosidase
due to either homozygosity for c.525delT (pt 7) or
c.2741delinsCAG (pt 4), or to compound heterozygosity for
c.525delT and c.378_379del (pt 8). Based on the outcome of
this analysis, eight of the 11 patients were designated CRIM-
positive and three CRIM-negative.
As an alternative approach determining the patients’ CRIM
status, we introduced the mutations in a GAA cDNA expres-
sion construct and studied their isolated effect on acid α-
glucosidase synthesis and maturation in HEK293T cells
(Fig. 2). Transient expression of the five missense mutations
identified among the patients in this study revealed synthesis
of the 110 kD acidα-glucosidase precursor with either normal
(c.1933G>T, c.1913G>T, and c.1115A>T) or slightly higher
than normal (c.1460 T>C and c.1799G>A) molecular mass.
The c.1799G>A and c.1460 T>C encoded precursors were
also clearly present in the culture medium, but the c.1933G>
T, c.1913G>T, and c.1115A>T encoded precursors were not
(Fig. 2; medium). Figures 1 and 2 both illustrate that the
conversion from 110 kD to 95 kD is not blocked completely
in the c.1799G>A construct; even the 76 kD form was
detectable.
Transient expression of c.2741delinsCAG did not reveal
any acid α-glucosidase species (Fig. 2; cells) and also this
finding is consistent with the lack of acid α-glucosidase
expression in fibroblasts of the patient who is homozygous
for this mutation (Fig. 1). None of the mutagenized cDNA
constructs led to expression of acid α-glucosidase activity in
the transfected cells nor in the medium.
On the basis of these two types of analyses, patients 4, 7,
and 8 were designated CRIM-negative; the other eight pa-
tients were designated CRIM-positive.
Antibody titers
All patients developed antibodies to alglucosidase alfa
(Supplemental Fig. 1a, Table 2). Over 4 years of treatment the
Table 1 Baseline characteristics
Parameters at start of ERT
Pt Gender Ethnic origin Age (months) Resp. function AIMS score LVMI in SD Genotype
1 M Turkish 0.1 OS N +5 c.1460 T>C
c.1460 T>C
2 F Caucasian 0.5 OS N +22 c.2481+102_2646+31del
c.2481+102_2646+31del
3 M Caucasian 1.2 NS A +15 c.1933G>T
c.525delT
4 M Turkish 1.9 NS N +30 c.2741delinsCAG
c.2741delinsCAG
5 M Caucasian 2.2 NS N +10 c.2481+102_2646+31del
c.525delT
6 F Caucasian 2.4 NS A +23 c.2481+102_2646+31del
c.2481+102_2646+31del
7a F Caucasian 3.0 NS A +31 c.525delT
c.525delT
8 F Caucasian 3.6 OS A +24 c.378_379del
c.525delT
9a M Caucasian 3.8 NS N +14 c.2481+102_2646+31del
c.1799G>A
10a F Caucasian 7.2 IV Ab +18 c.1115A>T
c.525delT
11a F Caucasian 8.3 OS Ab +68 c.1913G>T
c.1548G>A
Male 45 % Caucasian 81 % Median 3.0 Ventilated 9 % Median +22
Pt patient,Mmale, F female, Resp respiratory,OS oxygen via nasal cannula,NS no respiratory support, IV invasive ventilation,Nwithin normal range of
healthy peers, A atypical motor development (AIMS score ≤ −2SD), LVMI left ventricular mass index, SD standard deviation
a These patients initially received recombinant human acid α-glucosidase from transgenic rabbits
b Paresis arms and paralysis legs
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median peak antibody titer (ELISA) was 1:31,250 (range
1:1250–1:156,250). These titers were reached within 1 year
of ERT. Both low and high antibody titers were measured in
CRIM-positive (median 1:18,750, range 1:1250–1:156,250)
and CRIM-negative patients (median 1:31,250, range 1:6250–
1:156,250). The peak antibody titers tended to be higher in
patients who had started ERT relatively late (Table 2). Nota-
bly, none of the patients who received ERT before the age of
2 months developed titers above 1:6250.
Six patients (pts 5–8, 10 and 11) developed titers≥1:31,250
(Table 2); titers remained high in five cases and declined
temporarily to 1:6250 in one case (pt 10). The antibody titers
of the other five patients remained ≤1:6250 over the entire
study period; one of these patients was CRIM-negative and
his titer eventually declined to 1:50. There was no apparent
relationship between the titer and the dose of ERT, nor be-
tween the titer and the use of recombinant human acid α-
glucosidase from either rabbit milk or CHO cells (results not
shown).
An immunoprecipitation assay was used as an alternative
method for determining the antibody titer, for which we
selected three patients whose respective ELISA titers were
1:1250, 1:6250, and 1:156,250. The results are shown in
Supplemental Fig. 2 and are consistent with the outcome of
the ELISA assay in that both methods discriminate similarly
between a low, intermediate and high titer.
Inhibition of alglucosidase alfa uptake
To measure the effect of antibodies on the uptake of
alglucosidase alfa, we used sera of all patients at the time that
their antibody titer was highest (Supplemental Table 1).
Alglucosidase alfa and patients’ sera were added together to
the culture media of fibroblasts from a CRIM-negative infant.


















Fig. 1 Molecular forms of acid
α-glucosidase in fibroblasts. Cell
homogenates were prepared as
described in materials and
methods. Equal amounts of
protein were loaded per lane.
SDS-PAGE followed by
immunoblotting was used to
reveal the biosynthetic forms of
acid α-glucosidase. The numbers
under the lanes refer to the patient
numbers. The genotypes of the
patients are presented above the
lanes (delexon18 or del18 stands
for c.2481+102_2646+31del;
p.W460X stands for c.1548G>A).

















GFig. 2 Transient expression of
wildtype and mutant acid α-
glucosidase cDNA constructs.
Hek293T cells were transfected
with wildtype (Wt) and mutant
cDNA constructs to study
abnormalities in the synthesis and
post-translational modification of
acid α-glucosidase. To visualize
the molecular species, the same
procedure was used as in Fig. 1.
*Nonspecific background
staining
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No effects on enzyme activity or uptake of alglucosidase alfa
were observed when antibody titers were ≤1:6250.
Alglucosidase alfa activity in the medium was substantially
inhibited (26–50 % loss of enzymatic activity) by one of three
sera with a titer of 1:31,250 and by all three sera with a titer of
1:156,250. Only the three sera with the highest titer
(1:156,250) resulted in inhibition (24–42 %) of alglucosidase
alfa uptake.
Clinical outcome over 4 years of ERT
Survival and ventilator-free survival
One of the 11 patients was ventilator dependent before the
start of ERT. Over 4 years of ERT, four more patients required
invasive ventilation (at ages 0.9, 2.0, 2.2, and 2.7 years;
Table 2) and three patients died (at ages 0.6, 4.3, and
4.4 years). The last antibody titers measured before the pa-
tients’ deaths or respiratory insufficiency ranged from 1:50 to
1:31,250. The median peak antibody titer of these patients was
1:31,250 (range 1:6250–1:156,250); the median peak anti-
body titer of the five patients who are still alive and
ventilator-free at the time of reporting was 1:6250 (range
1:1250–1:31,250). All three CRIM-negative patients died.
All eight CRIM-positive patients are alive; two of them be-
came ventilator dependent during treatment.
Motor outcome
Supplemental Fig. 1C depicts motor development over time as
measured by AIMS. Over 4 years of ERT, eight patients
achieved important motor milestones. Six learned to walk
and two learned to sit, but three made minimal motor gains.
The median peak titer of the six patients who learned to walk
was 1:6250 (range 1:1250–1:31,250) against 1:31,250 (range
31,250–156,250) for the patients who did not learn to walk.
One of the three CRIM-negative patients and five of the eight
CRIM-positive patients learned to walk.
Patients 1 and 4 lost their ability to walk after developing
respiratory insufficiency. Their antibody titers never rose
above 1:6250. One of them was CRIM-positive, the other
CRIM-negative. One other CRIM-positive patient with a peak
titer of 1:31,250 temporarily lost the ability to attain a sitting
position after a respiratory syncytial virus (RSV) infection at
the age of 1.3 years (Supplemental Fig. 1c, pt 5). None of the
patients with a longer than 4 years follow-up lost or gained
motor milestones beyond 4 years of ERT.
Cardiac dimensions
At the start of ERT, all patients had hypertrophic cardiomy-
opathy. Over 4 years of ERT, the LVMI decreased significant-
ly in all but one patient who died 4 months after ERT was
Table 2 CRIM status, antibody titer, and clinical outcome
Age Antibody titer Clinical outcome at 4 years of ERTb





















1 0.1 5.6 + 1:6,250 1:1,250 1:6,250 (5.0) Y Y 2.7 (1:250) Sittinge −0.6 40f
2 0.5 8.0 + 1:1,250 1:250 1:250 (7.1) Y N Walking −0.7 20
3 1.2 8.5 + 1:6,250 1:1,250 1:6,250 (8.0) Y N Walking −1.5 40f
4 1.9 4.4a − 1:6,250 1:50 1:50 (3.4) Y Y 2.0 (1:6,250) Sittinge +0.9 20
5 2.2 5.2 + 1:31,250 1:31,250 1:31,250 (4.0) Y N Sitting +1.1 40f
6 2.4 4.1 + 1:31,250 1:31,250 1:31,250 (3.0) Y N Walking +3.7 40
7 3.0 4.3a − 1:156,250 1:156,250 1:156,250 (3.8) Y Y 2.2 (1:31,250) Sitting +4.4 40f
8 3.6 0.6a − 1:31,250 1:31,250 1:31,250 (0.3) N N Minimal motor gain +28.6 20
9 3.8 14.1 + 1:6,250 1:250 1:6,250 (12.8) Y N Walking +0.4 40f
10 7.2 14.3 + 1:31,250 1:6,250 1:156,250 (12.9) Y Y 0.6d Tetraplegic +4.9 40f
11 8.3 14.3 + 1:156,250 1:156,250 1:156,250 (11.5) Y Y 0.9 (1:250) Tetraplegic +4.5 40f
Pt Patient number, ERT enzyme-replacement therapy, CRIM cross reactive immunological material, LVMI left ventricular mass index, SD standard
deviation
a Age at death
b Last available data are presented if patient did not yet receive 4 years of ERT
cAge in years (antibody titer around that time)
d Patient was ventilator dependent before start of ERT
e Patients lost ability to walk
f Dose was augmented to 40 mg/kg/week during treatment
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initiated (Supplemental Fig. 1b). Six of the 11 patients had a
normal LVMI at 4 years of ERT.
The median peak antibody titer of the patients with a
normal LVMI after 4 years of ERT was 1:6250 (range
1:1,250–31,250) against 1:31,250 (range 1:6250–1:156,250)
for those whose LVMI was increased. The LVMI remained
above the reference value in all three CRIM-negative patients,
against two of the eight CRIM-positive patients. Beyond
4 years of ERT, no major changes in LVMI were observed.
Infusion-associated reactions
Over 4 years of ERT, ten of the 11 patients (82 %) experienced
one or multiple IARs. The first IARs started 0.4–24.5 months
after the start of ERT and comprised the following signs and
symptoms: General malaise, hypoxia, bronchospasm, dys-
pnea, tachycardia, bradycardia, hypotension, cyanosis, sweat-
ing, fever, vomiting, flushing, and exanthema. All IARs could
be controlled by slowing the infusion rate, with or without the
administration of premedication.
The only patient who did not develop IARs was CRIM-
positive and had the lowest peak antibody titer over the whole
period of reporting.
Discussion
Several studies have shown that antibody formation can occur
in patients receiving recombinant human proteins for therapy
(Wang et al 2008; Kishnani et al 2010; Banugaria et al 2011;
Patel et al 2012). Our patients with classic infantile Pompe
disease who were treated with alglucosidase alfa showed
various immune response patterns. Low and high titers were
measured in CRIM-negative and CRIM-positive patients
alike. While thorough statistical analysis was prevented by
the small sample size and the heterogeneity of our patient
population, we noticed that patients who did not learn to walk
had a relatively high titer. We also noticed that patients who
had started ERT before the age of two months tended to have
lower titers than those who had started later. Notably, all
CRIM-positive patients were still alive at the time of
reporting, whereas all CRIM-negative patients had died.
GAA genotypes and CRIM status
The quality and quantity of acid α-glucosidase in Pompe
disease depends on the GAA genotype. Ten different muta-
tions were identified, all causing complete loss of acid α-
glucosidase activity.
The commonly used procedure to determine the CRIM
status is immunoblotting and normally reveals four distinct
acid α-glucosidase species that separately and collectively are
called CRIM. In healthy people (Fig. 1, Wt), the long-lived 76
and 70 kD species comprise approximately 80 % of the total
CRIM. In patients, however, the synthesis of acid α-
glucosidase can be totally lost, which results in a CRIM-
negative status. More often, the synthesis is derailed, and
CRIM consists mainly of the 110 kD precursor (e.g., Fig. 1,
pts. 1 and 3) or a modified derivative thereof (Fig. 1, pts. 2 and
6). As it stands, the CRIM-negative status is well defined, but
the CRIM-positive status encompasses a collection of quali-
tatively and quantitatively abnormal immunoblot profiles.
By and large, a patient’s CRIM status can be predicted on
the basis of its genotype (Bali et al 2012). Most non-sense
mutations and frame-shift mutations lead to mRNA decay and
a CRIM-negative status (e.g., 525delT in pt. 3), truncated
protein species are sometimes detectable by immunoblotting
(e.g., c.2481+102_2646+31del in pts. 1, 7, 10, and 11), and
thus lead to a CRIM-positive status. Although the effect of
missense mutations is hard to predict, they usually lead to a
CRIM-positive status.
Information on the effect of missense mutations can be
obtained by transient expression (Fig. 2), which is especially
informative for the stage at which mutant forms of acid α-
glucosidase are degraded. For instance, the c.1460 T>C or
c.1799G>A encoded acid a-glucosidase precursors must have
traversed the Golgi complex since they are secreted into the
medium, whereas the c.1833G>T, c1913G>Tand c1115A>T
encoded precursors do not appear in the medium (Fig. 2) and
are apparently degraded while passing through the ER/Golgi
complex. By the current definition of CRIM, these five mis-
sense mutations lead to a CRIM-positive status, but obviously
do not represent one and the same CRIM-positive condition.
Our application of both methods to determine the CRIM
status resulted in the same outcome: eight patients are CRIM-
positive and three are CRIM-negative. Notably, the patient
homozygous for c.2741delinsCAGwas previously designated
CRIM-positive (Hermans et al 1998; Banugaria et al 2011).
CRIM status and antibody titer
Antibody formation is a natural response to foreign invading
proteins. Thus, ERT is prone to evoke an immune response in
CRIM-negative patients, but not necessarily in all CRIM-
positive patients. Patients with Pompe disease receiving ERT
respond roughly according to these principles. Analysis of the
immune response in 34 treated infants showed a strong ten-
dency toward higher and sustained antibody titers in CRIM-
negative compared to CRIM-positive infants (Kishnani et al
2010). However, CRIM-positive patients can also develop
high titers (Banugaria et al 2011), and CRIM-negative patients
low titers (Abbott et al 2011; Al Khallaf et al 2013). Our study
in 11 infants has led to similar findings. The highest peak
antibody titers were measured in four of the eight CRIM-
positive patients and in two of the three CRIM-negative
patients. The antibody titer of the third CRIM-negative patient
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did not exceed 1:6250 and spontaneously regressed to 1:50
after 3 years of ERT. There were two CRIM-positive patients
with the sameGAA genotype; one developed a relatively high
titer, and the other a relatively low titer.
Although the number of patients in our study is small, we
can firmly conclude that the CRIM status alone predicts
neither the level nor the duration of the immune response.
This may relate to the imprecise definition of CRIM status,
which does not describe the amount, the conformation or the
location of the endogenous acid α-glucosidase. For instance,
secretion of the 110 kD precursor as opposed to intracellular
degradationmight reduce the immune response and contribute
to the relatively low antibody titers in patients 1 and 9.
Notably, adult patients with a considerable amount of normal-
ly structured and catalytically active acid α-glucosidase can
also develop high titers (van der Ploeg et al 2010; deVries et al
2010; Patel et al 2012; Regnery et al 2012). Altogether, we
conclude that genotype and CRIM status are of limited value
in predicting the height of the immune response.
As previously suggested (van Gelder et al 2012; Al Khallaf
et al 2013), our study indicates that the age at start of ERT
might play a role in the immune response since none of the
patients who started ERT before 2 months of age developed
titers > 1:6250. There are at least two plausible explanations
for this: First, the neonatal immune system is immature, and
very early administration of ERT might induce tolerance
(Brooks 1999; Dierenfeld et al 2010). Second, the ‘danger
model’ suggests that the immune system needs alarm signals
from injured tissues to be activated. At a less advanced stage
of disease these signals will be weaker (Matzinger 2002).
Other models may equally apply.
Consequences of antibody formation
Depending on their binding sites antibodies can inhibit cata-
lytic function, block binding to the mannose 6-phosphate
receptor and prevent uptake, or otherwise misdirect the protein
to macrophages and neutrophils (Brooks et al 2003; Wang
et al 2008). Antibodies and antigen can also form immune
complexes and trigger a cascade of adverse events (Hunley
et al 2004).
In a previous case-report about an adult patient with Pompe
disease we have calculated how the concentration of
alglucosidase alfa specific antibodies relates to the concentra-
tion of alglucosidase alfa during enzyme infusion (de Vries
et al 2010). In the present study we have applied the same
arithmetic method to infants. For example, patient 11 had an
ELISA titer of 1:156,250 at a certain point of treatment. At
that time the corresponding titer as measured by immune-
precipitation was 40 nmol MUGlc/h.μL (Supplemental
Fig. 2) implying that 1 mL of the patient’s serum contained
enough antibodies to bind 0.13 mg alglucosidase alfa (de
Vries et al 2010). As a child receives 0.24 mg of alglucosidase
alfa per mL blood (based on 20 mg/kg and a circulating blood
volume of 80 mL/kg), antibodies may bind as much as 54 %
of the administered enzyme. By contrast, if the titer is only
4 nmol MUGlc/h.μL, corresponding with an ELISA titer of
1:6250, the circulating antibodies can bind only 5 % of the
administered aglucosidase alfa.
Although these estimates are crude they indicate that
ELISA titers of 1:6250 and lower probably have no clinical
significance, whereas titers of 1:31,250 and higher may coun-
teract ERT at a dose of 20 mg/kg. Accordingly, titers above
1:60,000 are expected to counteract ERT at a dose of
40 mg/kg. Our arithmetic estimates of what should be consid-
ered a high titer and what should be considered a low titer
remarkably correspond to the cut-off value of 1:51,200 chosen
by Banaguria et al (Banugaria et al 2011).
Antibodies can impede the effect of ERT in several ways.
In four cases we observed a decrease of catalytic activity
suggestive for binding of antibodies to the enzyme’s active
site. Uptake was inhibited in three cases. In one case this was
due to a combination of inactivation and uptake inhibition
possibly by steric hindrance of the ligand-receptor binding. Of
note, the effect of antibodies not only depends on the binding
sites but also on the stoichiometry of antibodies and
alglucosidase alfa in the experimental setting; changing the
concentration of one of the two components can tip the
balance. Whereas neutralizing antibodies were reported to be
more common in CRIM-negative than in CRIM-positive pa-
tients (Kishnani et al 2010; Banugaria et al 2011), in our study
their presence was not related specifically to the patients’
CRIM status but to the patients’ antibody titer.
It has been shown that high antibody titers in CRIM-
negative as well as CRIM-positive patients are associated with
shorter ventilator-free survival (Kishnani et al 2010;
Banugaria et al 2011). In several adults with Pompe disease,
a high titer was also accompanied by poor response to ERT
(de Vries et al 2010; Patel et al 2012). Although our study
group was too small and too varied to permit statistical anal-
ysis, patients with higher titers tended to attain fewer motor
milestones. However, with respect to ventilator-free survival,
only two of the six patients who developed respiratory insuf-
ficiency or died had a titer of ≥ 1:31,250 at the time that these
events occurred. Two other patients had low titers, but never-
theless developed respiratory insufficiency at the age of 2.
Two patients became ventilator dependent just before or soon
after the start of ERT which we ascribe to their advanced
disease at the start of ERT.
Conclusions and challenges
The outcome of classic infantile Pompe patients is determined
by many factors, among which are the age and disease sever-
ity at initiation of ERT, the patient’s genotype, and the height
of the antibody response. It is beyond question that high and
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sustained antibody titers need to be prevented in order to
achieve a good response to ERT (Kishnani et al 2010; de
Vries et al 2010; Banugaria et al 2011). Our study indicates
that the negative effect of antibodies starts at an antibody titer
of approximately 1:31,250 when the recommended dose of
20 mg/kg is used. Very early start of ERT (<2 months),
achievable by neonatal screening, may help to keep the anti-
body titers low. Recent publications indicate that immune
tolerance can be successfully induced by a combination of
rituximab, methotrexate, and intravenous immunoglobulins
(Mendelsohn et al 2009; Messinger et al 2012; Banugaria
et al 2013b), a regimen likely to be most effective when used
prophylactically (Lacaná et al 2012; Banugaria et al 2013a).
As the patients’ genotype and related CRIM status alone are
obviously not the sole determinants for the patients’ immune
response, identification of other triggering factors remains a
challenge. Though the number of patients is very small, it
occurred to us that the three CRIM-negative patients in our
study had an early demise while all CRIM-positive patients
survived. If the difference is not made solely by the CRIM-
status or antibody titer, might it be that CRIM-positive patients
can have a tiny bit of acid α-glucosidase activity in their
tissues that we cannot detect with our current methods?
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